Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Multicentre, Open-label Phase II Trial Investigating Activity of Chemotherapy and Lapatinib and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer (MBC) Refractory to Anti HER2 Therapies

NCT02238509 is registered in ClinicalTrials.gov with Consorzio Oncotech as lead sponsor.

NCT NCT02238509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02238509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Multicentre, Open-label Phase II Trial Investigating Activity of Chemotherapy and Lapatinib and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer (MBC) Refractory to Anti HER2 Therapies
Lead sponsor
Consorzio Oncotech
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2014
Completion date
October 31, 2017
Enrollment
154 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer